Piper Jaffray Cos. lowered shares of ViroPharma (NASDAQ:VPHM) from an overweight rating to a neutral rating in a research report released on Monday morning, TheFlyOnTheWall.com reports.
Shares of ViroPharma (NASDAQ:VPHM) traded up 0.16% during mid-day trading on Monday, hitting $49.50. 8,615,626 shares of the company’s stock traded hands. ViroPharma has a 52 week low of $22.12 and a 52 week high of $49.52. The stock has a 50-day moving average of $39.44 and a 200-day moving average of $32.37. The company’s market cap is $3.249 billion.
ViroPharma (NASDAQ:VPHM) last announced its earnings results on Thursday, October 24th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.15. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $113.35 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. Analysts expect that ViroPharma will post $-0.63 EPS for the current fiscal year.
A number of other firms have also recently commented on VPHM. Analysts at Leerink Swann raised their price target on shares of ViroPharma from $34.00 to $37.00 in a research note to investors on Friday, November 1st. They now have a market perform rating on the stock. Separately, analysts at JMP Securities raised their price target on shares of ViroPharma from $38.00 to $43.00 in a research note to investors on Friday, November 1st. Finally, analysts at Cowen and Company raised their price target on shares of ViroPharma from $26.00 to $27.00 in a research note to investors on Friday, November 1st. They now have a market perform rating on the stock. Two analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the stock. ViroPharma has a consensus rating of Hold and an average target price of $39.23.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.